Dr. Rebecca Haffajee is an Assistant Professor of Health Management and Policy at
the University of Michigan School of Public Health. She received her law degree from
Harvard Law School and a Masters in Public Health from Harvard School of Public Health
in 2006. She practiced as a health care associate in the law firm of Ropes & Gray
LLP from 2006-2009, where she advised domestic health care providers on regulatory
compliance and reimbursement matters. From 2009-2010, she served as a Law Fellow at
the O’Neill Institute for National and Global Health Law at Georgetown University
Law Center. Dr. Haffajee completed her PhD in Health Policy with a concentration in
Evaluative Science and Statistics at Harvard University in 2016.
Dr. Haffajee’s research combines detailed legal analyses with empirical investigations of the relationships between law and health. She substantively focuses in the behavioral health and pharmaceutical policy areas, evaluating policies such as mental health/substance abuse parity and laws intended to curb opioid addiction and misuse, such as prescription drug monitoring programs. Her work has been funded by the Robert Wood Johnson Foundation, the National Institute of Mental Health, and the Centers for Disease Control and Prevention. She is the recipient of the 2017 AcademyHealth Outstanding Dissertation Award for “Evaluating Legal Interventions Designed to Improve Behavioral Health Outcomes.”
HMP 653 – Law and the Public’s Health
Ph.D., Health Policy (Evaluative Science & Statistics), Harvard University, 2016
J.D., Harvard Law School, 2006
M.P.H., Law & Public Health, Harvard School of Public Health, 2006
B.A., Women’s Studies Program & Certificate in Health Policy, Duke University, 2002
- Haffajee RL, Mello MM, Zang F, Zaslavsky A, Larochelle MR, Wharam JF. Four states with robust
prescription drug monitoring programs reduced opioid dosages. Health Aff 2018. In
- Kennedy-Hendricks A, Epstein AJ, Stuart EA, Haffajee RL, McGinty EE, Busch AB, Huskamp H, Barry CL. Federal parity and spending for mental
illness. Pediatrics 2018. In press.
- Haffajee RL, Bohnert ASB, Lagisetty PA. Policy pathways to address workforce barriers to buprenorphine
treatment. Am J Prev Med 2018. In press.
- Haffajee RL, Frank RG. Making the opioid emergency effective. JAMA Psych Online First; Apr. 25,
- Haffajee RL, Mello MM. Drug companies’ liability for the opioid epidemic. N Engl J Med 2017;377(24):2301-2305.
- Yang TY, Larochelle MR, Haffajee RL. Managing increasing liability risks related to opioid prescribing. Am J Med 2017;130(3):249-50.
- Yang TY, Haffajee RL. Murder liability for prescribing opioids: a way forward? Mayo Clin Proc 2016; 91(10):1331-35.
- Haffajee RL. Preventing opioid abuse with prescription drug monitoring programs: a framework
for evaluating the success of state public health laws. Hastings Law J 2016; 67(6):1621-1694
(ranked 33/986 U.S. law journals).
- Haffajee RL, Jena AB, Weiner SG. Mandatory use of prescription drug monitoring programs. JAMA
- Haffajee RL, Parmet WE, Mello MM. What is a public health “emergency”? N Engl J Med 2014;371(11):986-988.
- Haffajee RL, Bloche GM. The FCTC and the psychology of tobacco control. Asian J WTO Int’l Health
Law & Pol’y 2010;5(1): 87-113.
- Haffajee RL. The potential use of joint criminal enterprise theory in prosecuting crimes of rape and sexual violence at the ICTR. Harvard J Law & Gender 2006;29(1):201-221.
- Academy Health
- American Public Health Association
- American Society of Law, Medicine & Ethics
- Society for Empirical Legal Studies